Premium
Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy
Author(s) -
Wang Xiupeng,
Li Xia,
Yoshiyuki Kazuko,
Watanabe Yohei,
Sogo Yu,
Ohno Tadao,
Tsuji Noriko M.,
Ito Atsuo
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201501013
Subject(s) - mesoporous silica , adjuvant , cancer immunotherapy , immune system , immunoadjuvant , immunotherapy , in vivo , spleen , lymph node , immunopotentiator , materials science , cancer research , chemistry , immunology , medicine , mesoporous material , biology , biochemistry , microbiology and biotechnology , catalysis
A plain mesoporous silica nanoparticle without any immunomodulatory molecules significantly enhances anticancer immunity in vivo. Comprehensive mechanism of mesoporous‐silica‐nanoparticle‐induced cancer immunotherapy is analyzed in this paper. The mesoporous silica nanoparticle promotes both Th1 and Th2 immune responses, as it accelerates lymphocytes proliferation, stimulates IFN‐γ, IL‐2, IL‐4, and IL‐10 cytokine secretion by lymphocytes ex vivo, and increases IgG, IgG1, IgG2a, IgM, and IgA antibody titers in mice serum compared with those of alum and adjuvant‐free groups. Moreover, the mesoporous silica nanoparticle enhances effector memory CD4 + and CD8 + T cell populations in three most important immune organs (bone marrow, lymph node, and spleen) of mice compared with those of alum and adjuvant‐free groups three months after adjuvant injection. The present study paves the way for the application of mesoporous silica nanoparticle as immunoadjuvant for cancer immunotherapy.